0
Original Research: PROLONGED MECHANICAL VENTILATION |

Survival of Patients With Kyphoscoliosis Receiving Mechanical Ventilation or Oxygen at Home*

Torbjörn Gustafson, MD, FCCP; Karl A. Franklin, MD, PhD, FCCP; Bengt Midgren, MD, PhD; Kerstin Pehrsson, MD, PhD; Jonas Ranstam, PhD Cstat; Kerstin Ström, MD, PhD
Author and Funding Information

*From the Department of Medicine (Dr. Gustafson), Skellefteå Hospital, Skellefteå, Sweden; the Department of Respiratory Medicine (Dr. Franklin), University Hospital, Umeå, Sweden; the Department of Respiratory Medicine (Dr. Midgren), University Hospital, Lund, Sweden; the Department of Respiratory Medicine and Allergology (Dr. Pehrsson), Sahlgrenska University Hospital, Göteborg, Sweden; Mdas AB (Dr. Ranstam), Lund, Sweden; and the Department of Respiratory Medicine (Dr. Ström), Blekinge Hospital, Karlskrona, Sweden.

Correspondence to: Torbjörn Gustafson, MD, FCCP, Department of Medicine, Skellefteå Hospital, SE-931 86 Skellefteå, Sweden; e-mail: torbjorn.gustafson@vll.se



Chest. 2006;130(6):1828-1833. doi:10.1378/chest.130.6.1828
Text Size: A A A
Published online

Background: Home mechanical ventilation (HMV) and long-term oxygen therapy (LTOT) are the two treatment alternatives when treating respiratory insufficiency in patients with kyphoscoliosis. We aimed to study the effect on survival with regard to HMV or LTOT alone in patients with respiratory insufficiency due to kyphoscoliosis.

Methods: Swedish patients with nonparalytic kyphoscoliosis (ie, scoliosis not related to neuromuscular disorders) who started LTOT or HMV between 1996 and 2004 were followed up prospectively until February 14, 2006, with death as the primary outcome. Treatment modality, arterial blood gas levels, the presence of concomitant respiratory diseases, and age were recorded at the onset of treatment. No patient was lost to follow-up.

Results: One hundred patients received HMV, and 144 patients received oxygen therapy alone. Patients treated with HMV experienced better survival, even when adjusting for age, gender, concomitant respiratory diseases, and blood gas levels, with a hazard ratio of 0.30 (95% confidence interval, 0.18 to 0.51).

Conclusion: The survival of patients with kyphoscoliosis receiving HMV was better than that of patients treated with LTOT alone. We suggest HMV and not oxygen therapy alone as the primary therapy for patients with respiratory failure due to kyphoscoliosis, regardless of gender, age, and the occurrence of concomitant respiratory diseases.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543